sharecast

{{ storiesRelated.title }}

News And Announcements
24 Jul
doctors, medical, hospital, health, Glaxosmithkline
Convatec wins US clearance for innovative wound dressing

ConvaTec's Aquacel Ag Advantage dressing, which helps treat non-healing wounds, has been given the nod by the US medical regulator.

24 Jul
spectris
Spectris profit rises but sketchy Uplift update disappoints

Spectris shares fell after the precision instruments maker flagged up slowing sales growth and left investors guessing about the next phase of a delayed efficiency drive.

24 Jul
outdoor summer roast dish meal food 714494 pxhere
Sainsbury's trails rivals as supermarkets enjoy summer boom

Sainsbury's sales rebounded in recent weeks but it continues to lag behind its big supermarket rivals as all of the big four enjoyed their best period of growth so far this year.

24 Jul
PZ Cussons profit falls as Nigerian consumers feel squeeze

PZ Cussons’ annual profit fell by almost a quarter as the consumer goods company felt the effect of squeezed consumer spending in Nigeria and to a lesser extent the UK.

24 Jul
Drax power station, energy generator, electricity, power
Drax earnings slide in first half after unplanned outages

Drax Group posted its half-year results to 30 June on Tuesday, reporting that while its full-year expectations remained unchanged, its first half was impacted by two unplanned outages.

24 Jul
retail shopping consumer hammerson
Hammerson rental income slips as it prepares to exit retail parks

Hammerson posted its half-year report on Tuesday, reporting stability in valuations as well as earnings per share at 15. 1p, and also announced a reshaped strategy to “elevate and accelerate” performance.

24 Jul
bt, openreach, cable, broadband, internet
BT offers discounts to ISPs in push for faster broadband

BT Group has offered discounts for internet service providers to upgrade customers to faster broadband as the government seeks to overhaul Britain's digital network.

24 Jul
astrazeneca
AstraZeneca offloads Atacand rights in $200m deal

AstraZeneca has agreed to sell the commercial rights to Atacand - candesartan cilexetil - and Atacand Plus - a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide - in Europe to Cheplapharm Arzneimittel, it announced on Tuesday.

24 Jul
britvic
Britvic growth stymied by CO2 shortage

Fizzy drinks maker Britvic said it was held back from fully capitalising on the hot weather in the third quarter due to the UK shortage of carbon dioxide.